

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/644,671
				Filing Date	Herewith
				First Named Inventor	Coyle, Anthony J., et al.
				Group Art Unit	164
				Examiner Name	I. OUSPENSKI
				Attorney Docket Number	MPI00-212CP1CN1M
Sheet 1		of 1			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)
		Number	Kind Code <sup>2</sup> (if known)		
JO	A1	5,521,288		Linsley et al.	05/28/1996
	A2	5,861,310		Freeman et al.	01/19/1999
	A3	5,942,607		Freeman et al.	08/24/1999
	A4	5,968,510		Linsley et al.	10/19/1999
	A5	US-2002/0095024	A1	Mikesell et al.	7-2002
	A6	US-2002/0164600	A1	Freeman et al.	11-2002

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)
		Office <sup>3</sup>	Kind Code <sup>5</sup> Number <sup>4</sup> (if known)		
	B1	WO	96/40915	Dana-Farber Cancer Institute	12/19/1996
	B2	EP	1074617	Helix Res Inst	February 7, 2001
	B3	WO	01/83750	A Tseng et al.	November 8, 2001
	B4	WO	01/94413	A Squibb Bristol Myers	December 13, 2001
	B5	WO	01/34629	A Human Genome Sciences Inc	May 17, 2001
	B6	WO	00/55375	A Alphagene Inc	September 21, 2000
	B7	WO	00/37643	A Corixa Corp	June 29, 2000
	B8	WO	01/49716	A Corixa Corp	July 12, 2001
	B9	WO	00/61612	A Corixa Cor.	October 19, 2000
	B10	WO	97/24447	A Viagene Inc	July 10, 1997
	B11	WO	95/05464	A Arch Dev Corp	February 23, 1995
JO	B12	WO	95/03408	A Dana Farber Cancer Inst Inc	February 2, 1995

Examiner Signature	<i>Ilia Ouspenski</i>	Date Considered	02/21/2007
--------------------	-----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

**COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
(use as many sheets as necessary)					
Sheet	1	of	2	Attorney Docket Number	MPI00-212CP1CN1M

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JO	C1	Database EMBL Sequence Database [Online] Hinxton, UK; 1 June 1999 (1999-06-01) S. Y. Tseng et al.: "Mus Musculus Butyrophilin-like (Btdc) mRNA, Complete cds." EMBL Sequence Accession No. AF142780	
	C2	Database EMBL Sequence Database [Online] Hinxton, UK; 22 February 2000 (2000-02-22) T. Isogai and T. Otsuki: "Homo Sapiens cDNA FLJ11010 fis, clone PLACE1003145; XP002193892. EMBL Sequence Accession No. AK001872	
	C3	Gerstmayer, et al., <i>Cancer Immunology Immunotherapy</i> 45(3-4): 156-158 (1997)	
	C4	Schwartz, et al., <i>Nat. Immunol.</i> 3(5):427-434 (2002)	
	C5	Inobe et al., <i>J. Immunol.</i> 157:582-588 (1996)	
	C6	ABBAS et al., <i>Nature Medicine</i> 5 (12) :1345-1346 (1999)	
	C7	DONG et al., <i>Nature Medicine</i> 5(12) :1365-1369 (1999)	
	C8	FARGEAS et al., <i>J. Exp. Med.</i> 182 :667-675 (1995)	
	C9	FREEMAN et al., <i>The FASEB Journal</i> 14(6) :Abstract 153.34, Pg. A1170 (2000)	
JO	C10	HUTLOFF et al., <i>Nature</i> 397:263-266 (1999)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

*Idia Aspasia* 02/21/2007

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	
Sheet	2	of	2	Filing Date	Herewith
				First Named Inventor	Coyle, Anthony J., et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	MPI00-212CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		
JO	C11	LING et al., <i>J. Immunol.</i> 164(4):1653-1657 (2000)		T <sup>2</sup>
	C12	MAGES et al., <i>Eur. J. Immunol.</i> 30 (4) :1040-1047 (2000)		
	C13	PEACH et al., <i>Journal of Biological Chemistry</i> 270(36) :21181-21187 (1995)		
JO	C14	YOSHINAGA et al., <i>Nature</i> 402(6763) 827-832 (1999)		

Examiner Signature	<i>Dian Owspeckhi</i>	Date Considered	02/21/2007
--------------------	-----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.